Big biotech Regeneron Pharmaceuticals (REGN) was down about 4.5% in early trading on the stock market today after reporting a mixed quarter and guidance. Valuation Level The valuation of Regeneron Pharmaceuticals, Inc.is done by analysts by using price-to-earnings ratio. Roth Capital maintained the shares of REGN in a report on April 4 with “Buy” rating. Brean Capital reinitiated it with “Buy” rating and $489 target price in a March 8 report. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $470.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 23rd. If the YTD value is Positive, this means the stock is appreciating. The 52-week high of the share price is $593.66 and the 52-week low is $329.09.
Advertisement
The stock has recorded a 20-day Moving Average of 12.16% and the 50-Day Moving Average is 12.74%. (NASDAQ:REGN) opened at 434.90 on Wednesday. The biopharmaceutical company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.65 by $0.17. Analysts expect the company to announce earnings of $2.62 per share and revenue of $1.24 billion for the quarter.
Fitbit, as of current trade, has shown weekly upbeat performance of 12.09 percent which was maintained at 21.28 percent in 1-month period. Year-to-Date the stock performance stands at -21.69%.
About 1.40M shares traded hands or 59.29% up from the average. Following the transaction, the executive vice president now owns 11,381 shares in the company, valued at approximately $4,390,448.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Regeneron Pharmaceuticals Inc makes up approx 0.05% of Ls Investment Advisors’s portfolio. Also, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction dated Friday, July 29th. The disclosure for this purchase can be found here.
Other Hedge Funds, Including, Terra Nova Asset Management sold out all of its stake in REGN during the most recent quarter.
Increased costs related to helping patients pay for Eylea, and securing reimbursement from health insurers, negatively impacted the drug’s profit margins in the second quarter, Robert Terifay, Regeneron’s sales chief, said on a conference call with analysts on Thursday.
Praluent and Repatha are now splitting market share evenly, Regeneron said, adding that some countries were still waiting on data from an ongoing study evaluating Praluent’s effect on cardiovascular risk.
Advertisement
Product Revenues: Net product sales were $834 million in the second quarter of 2016, contrast to $658 million in the second quarter of 2015. Grandfield & Dodd LLC now owns 1,175 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 48 shares in the last quarter.
